Clinical trial
A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder
NCT02045862 is registered in ClinicalTrials.gov with Astellas Pharma Europe B.V. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate With Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects With Overactive Bladder
- Lead sponsor
- Astellas Pharma Europe B.V.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- March 17, 2014
- Completion date
- September 8, 2016
- Enrollment
- 1,829 (actual)
- Sites
- 251
Conditions
As the registry lists them; a condition with its own page is linked.
overactive bladder, urgency incontinence, urinary bladder diseases\urologic diseases, urinary bladder overactive